Principal Consultant
CurrentProvide clients with strategic Technical Operations and Regulatory CMC leadership to develop and commercialize novel therapeutics.• Lead teams authoring Module 2 and 3 sections for INDs, BLAs, MAAs, and post-approval variations, including additional DS, DP sites, and additional presentations for biologics and combination products mAbs, antibody-drug conjugates, biologics, autologous cell therapies.• Direct strategic sourcing initiatives to identify API, DS, and Drug Product manufacturing sites review contracts, cell line licensing, and quality agreements, and initiate tech transfer or gene-to-clinic development.• Provide key point of contact interface between clients and CDMOs executing gene-to-clinic programs.• Perform CMC, Reg CMC Due-Diligence evaluating development, IND, and late-stage clinical assets.• Develop CMC Questions, represent client CMC Teams at FDA Type C Meetings, and solicit scientific Advice from other health authorities.• Determine Strategy, and manage responses to CMC questions from health agencies in North America, Europe, and the rest of the world, including complete response remediation and strategies to remove clinical hold on first-in-human trials• Redact/Revise dossiers to address regional requirements in ROW markets, including China, Brazil, GCC, etc.• Support submissions through MAA approvals in EU, China, Russia, Taiwan, Brazil, Saudi Arabia, etc.• Assess manufacturing facilities and tech transfer plans for clinical stage cell therapy products, and validation documents for a lentiviral vector process for CAR-T therapy.• Manage external development and manufacturing for biologics (CHO, E. coli, aspergillus) and small molecules.• Lead CMC tech Operations Activities for accelerated development of a novel-COVID related antibody treatment• Person-in-Plant services during tech transfer, PPQ, engineering, and clinical manufacturing.• Provide engineering procurement support for process-related capital expenses.